BEST TRIAL

A trial comparing long-term clinical and angiographic results of the BeStent and Palmaz-Schatz stent in native coronary lesions.

Primary endpoints
6-month major acute coronary events (MACE).

Conclusion
The BeStent is at least as safe and effective as the Palmaz-Schatz, with lower rates of target vessel and target lesion revascularisation; both cohorts had binary restenosis rates comparable to other stents.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.